Anti-VEGF immunotherapy with HEBERSaVax suppresses melanoma growth and metastasis via angiogenesis blockade and enhanced T-cell infiltration
IntroductionTargeting tumor angiogenesis through vascular endothelial growth factor (VEGF) blockade represents a promising strategy for melanoma treatment. Here, we evaluate the therapeutic potential of HEBERSaVax, an anti-VEGF active immunotherapy, in…